Marcial: The Formula for a Pfizer Recovery

The pharma stalwart is unloved by investors, but a cost-cutting program and an increased emphasis on cancer drugs could bring new life to the shares

A glance at the stock chart of Pfizer (PFE), the world's largest pharmaceutical company, could make you sick—if you own the stock. It is now trading at its 52-week low of $17.96 a share, down from $27 a year ago and way down from $50, where it was in 2000. After the vertigo, nausea, and other side effects of experiencing such a precipitous plunge, you might even think about calling your broker, if you haven't already, to sell the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.